FIG. 1.

Complement inhibition decreases tumor volume. a Tumor volumes of mice treated with PBS or CVF (500 μg/kg per mouse) measured at days 6 (78 vs. 44 mm³; p = 0.049), 12 (343 vs. 164 mm³; p = 0.019), and 16 (652 vs. 390 mm³; p = 0.03) after tumor establishment. Mice treated with CVF had significantly smaller tumors than those treated with PBS at all 3 time points. b Tumor volumes of mice treated with PBS or hCVF (1 mg/kg per mouse) measured at days 8 (54 vs. 29 mm³; p = 0.0015), 12 (82 vs. 42 mm³; p = 0.002), and 19 (222 vs. 99 mm³; p = 0.06) after tumor establishment. Mice treated with hCVF had significantly smaller tumors at days 8 and 12 after tumor establishment, but after this time point, significance was lost. c Tumor volumes of mice treated with PBS or CVF at a higher dose (1 mg/kg per mouse) measured at days 8 (282 vs. 90 mm³; p = 0.009) and 12 (613 vs. 152 mm³; p = 0.004) after tumor establishment. Mice treated with this dose of CVF had smaller tumors at days 8 and 12, but this difference was lost at later time points. d Tumor volumes of mice treated with PBS or SSL7 (100 μg IV day 2 and 12 after tumor establishment) measured at days 7 and 12 after tumor establishment. Mice treated with SSL7 had smaller tumors at days 7 (207 vs. 121 mm³; p = 0.001) and 12 (447 vs. 263 mm³; p = 0.005), but this difference was lost at later time points. *p < 0.05, **p < 0.01, ***p ≤ 0.001